CRSP - Company ID 0001674416
The table below shows CRISPR Therapeutics AG's balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $347.56M | $298.26M | $389.48M | $211.88M | $923.03M | $1.17B |
| Short-term investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $521.71M |
| Receivables | $0.00 | $25.00M | $200.00M | $0.00 | $305.00K | $144.00K |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $1.99B |
| $1.94B |
| $1.91B |
| $1.85B |
| $2.42B |
| $1.72B |
| Property, plant & equipment | $115.85M | $134.09M | $151.94M | $163.63M | $137.57M | $42.16M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B |
| Accounts payable | $11.14M | $14.71M | $38.15M | $27.43M | $14.82M | $9.09M |
| Total current liabilities | $149.12M | $87.78M | $108.79M | $121.11M | $119.88M | $94.26M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $343.43M | $309.95M | $346.77M | $367.58M | $352.42M | $163.73M |
| Retained earnings | -$1.95B | -$1.37B | -$999.70M | -$846.09M | -$195.91M | -$573.58M |
| Total equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B |